Boundless persevered with the other drug, a CHK1 inhibitor BBI-355, as a monotherapy for oncogene-amplified solid tumors. But the clinical data showed signs of hematological toxicity that would have ...
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026Portfolio prioritization, including ...
InvestorsHub on MSN
Boundless Bio secures FDA green light to launch cancer drug study
Boundless Bio (NASDAQ:BOLD) said it has received clearance from the Food and Drug Administration for its investigational new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results